M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Phase 2

Completed

Conditions: Mixed Tumor, Mullerian

Interventions: Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2007-07-17

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00502203

Locations: 🇺🇸
Lyndon Baines Johnson Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Loma Linda Cancer Institute, Loma Linda, California, United States

and more 1 locations

Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Doxorubicin
Radiation: Radiation Therapy

First Posted Date: 2007-07-17

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00502411

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients

Completed

Conditions: Lung Cancer
Colorectal Cancer
Anal Cancer
Esophageal Cancer
Gastric Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-17

Last Posted Date: 2012-07-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 205

Registration Number: NCT00502502

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Genetic Susceptibility in Migrant Farmworker Children

Completed

Conditions: Epidemiology

Interventions: Behavioral: Interview

First Posted Date: 2007-07-16

Last Posted Date: 2013-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 768

Registration Number: NCT00501280

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Recruiting

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Nelarabine
Drug: Pegaspargase
Drug: Prednisone
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2007-07-16

Last Posted Date: 2024-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT00501826

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Phase 3

Terminated

Conditions: Thrombocytopenia
Myocardial Infarction

Interventions: Drug: Aspirin

First Posted Date: 2007-07-16

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00501345

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Carboplatin
Drug: GM-CSF (Sargramostim)
Drug: Interferon Gamma

First Posted Date: 2007-07-16

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT00501644

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Tissue Repair in Stem Cell Transplant Recipients

Not Applicable

Terminated

Conditions: Graft-Versus-Host Disease

Interventions: Drug: Filgrastim

First Posted Date: 2007-07-16

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00501228

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: Cetuximab
Drug: Dasatinib
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2007-07-16

Last Posted Date: 2019-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00501410

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effect of Parathyroidectomy on Sleep

Not Applicable

Completed

Conditions: Hyperparathyroidism

Interventions: Procedure: Parathyroid Surgery
Behavioral: Telephone Interview
Behavioral: Polysomnography (PSG)

First Posted Date: 2007-07-16

Last Posted Date: 2017-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00501215

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy